Jennison Associates LLC Acquires Shares of 20,436 Collegium Pharmaceutical, Inc. $COLL

Jennison Associates LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 1st quarter, HoldingsChannel reports. The firm bought 20,436 shares of the specialty pharmaceutical company’s stock, valued at approximately $676,000.

A number of other institutional investors and hedge funds have also modified their holdings of COLL. Group One Trading LLC acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Collegium Pharmaceutical in the 4th quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares in the last quarter.

Wall Street Analysts Forecast Growth

COLL has been the topic of several research reports. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $57.50.

Collegium Pharmaceutical Stock Performance

COLL opened at $34.72 on Thursday. Collegium Pharmaceutical, Inc. has a twelve month low of $29.19 and a twelve month high of $50.79. The firm has a market capitalization of $1.13 billion, a PE ratio of 17.02 and a beta of 0.73. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The firm’s 50-day moving average price is $34.61 and its 200 day moving average price is $38.02.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the firm earned $1.49 EPS. Collegium Pharmaceutical’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.